FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
First-Ever Biologic Approved for COPD
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on Friday. An injectable interleukin (IL)-4 and IL-13 pathway inhibitor,
FDA Approves Dupixent for Some Patients Struggling With COPD Symptoms
Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD)
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.
Sanofi, Regeneron get USFDA nod for Dupixent for COPD
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients ...
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
AbbVie's (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech's (BNTX) COVID-19 shot ...
dermatologyadvisor16d
Dupilumab Looks Promising for Patients With Bullous Pemphigoid
Treatment with dupilumab led to significant improvements in remission in patients with bullous pemphigoid, an autoimmune blistering skin disease.
PharmiWeb2d
LEO Pharma Presents Late-Breaking Results from the…
LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the Phase 2a Mechanism of Action (MoA) trial, which assessed the mechanistic impact of investigational ...
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...